If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.00 (0.00%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Directorate Change

20 Sep 2018 07:01

RNS Number : 3208B
Venture Life Group PLC
20 September 2018
 

20 September 2018

Venture Life Group plc

("Venture Life" or the "Company")

 

Directorate Change

 

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces the appointment of Carl Dempsey as a Non-Executive Director to replace John Sylvester who has stepped down from the Board to focus on his other executive commitments. These Board changes take place with immediate effect.

 

Until recently, Carl was Worldwide Vice President Global Customer Management at Johnson & Johnson ("J&J") where he was responsible for global sales of US$3.6 billion across 22 countries. During his 29 year career at J&J, Carl had particular responsibility for developing the Health and Wellness Partnership strategy. He also led the successful integration of Pfizer Consumer Healthcare across Europe, Africa and the Middle East which included the Listerine mouthwash brand.

Dr Lynn Drummond, Non-Executive Chair of Venture Life, commented: "We are delighted to welcome Carl to the Board. His wide variety of international roles and experience gained in his long career at J&J will no doubt prove to be a valuable asset to the rest of the Board as we seek to continue growing the business both organically and via acquisitions.

 

"On behalf of the Board, I would like to thank John for his contribution to the Company. He has been with Venture Life since our IPO in 2014 and we have appreciated his guidance during this time and we wish him all the best for the future."

 

Further information on Carl Dempsey

 

Carl Douglas Dempsey (aged 56) has in the last five years been a director of Johnson & Johnson Consumer Services (EAME) Limited and is currently a director of Big Blue Bear Limited.

 

There is no further information on Carl Dempsey required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Cenkos Securities plc (Joint Broker)

+44 (0) 207 397 8900

Mark Connelly (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

Walbrook PR

venturelife@walbrookpr.com or + 44 (0) 20 7933 8780

Anna Dunphy / Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOABLGDCXDBBGIC
Date   Source Headline
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR
23rd Aug 20247:00 amRNSExercise of Options, Director Dealings & TVR
9th Aug 20241:17 pmRNSHolding(s) in Company
6th Aug 20247:00 amRNSTrading Update
25th Jul 20243:54 pmRNSHolding(s) in Company
11th Jul 202410:08 amRNSHolding(s) in Company
19th Jun 20242:46 pmRNSPosting of Annual Report
4th Jun 20243:34 pmRNSResult of AGM
4th Jun 20247:00 amRNSAGM Statement
23rd May 202411:35 amRNSExercise of Share Options & Total Voting Rights
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.